- Home
- GMAB vs ALLE Comparison
GMAB vs ALLE Comparison
Compare GMAB & ALLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ALLE
- Stock Information
- Founded
- GMAB 1999
- ALLE 2013
- Country
- GMAB Denmark
- ALLE Ireland
- Employees
- GMAB 2638
- ALLE N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ALLE Diversified Commercial Services
- Sector
- GMAB Health Care
- ALLE Consumer Discretionary
- Exchange
- GMAB Nasdaq
- ALLE Nasdaq
- Market Cap
- GMAB 13.4B
- ALLE 12.3B
- IPO Year
- GMAB N/A
- ALLE N/A
- Fundamental
- Price
- GMAB $22.25
- ALLE $139.60
- Analyst Decision
- GMAB Buy
- ALLE Hold
- Analyst Count
- GMAB 9
- ALLE 5
- Target Price
- GMAB $39.17
- ALLE $140.40
- AVG Volume (30 Days)
- GMAB 1.3M
- ALLE 918.3K
- Earning Date
- GMAB 05-08-2025
- ALLE 07-23-2025
- Dividend Yield
- GMAB N/A
- ALLE 1.46%
- EPS Growth
- GMAB 276.80
- ALLE 16.19
- EPS
- GMAB 18.36
- ALLE 7.12
- Revenue
- GMAB $3,230,902,140.00
- ALLE $3,820,200,000.00
- Revenue This Year
- GMAB $747.74
- ALLE $5.99
- Revenue Next Year
- GMAB $14.81
- ALLE $4.70
- P/E Ratio
- GMAB $1.21
- ALLE $19.59
- Revenue Growth
- GMAB 25.43
- ALLE 5.48
- 52 Week Low
- GMAB $17.24
- ALLE $113.27
- 52 Week High
- GMAB $28.56
- ALLE $156.10
- Technical
- Relative Strength Index (RSI)
- GMAB 64.68
- ALLE 50.04
- Support Level
- GMAB $20.88
- ALLE $137.64
- Resistance Level
- GMAB $22.15
- ALLE $139.90
- Average True Range (ATR)
- GMAB 0.39
- ALLE 2.12
- MACD
- GMAB 0.14
- ALLE -0.91
- Stochastic Oscillator
- GMAB 94.62
- ALLE 30.11
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.